Loading clinical trials...
Loading clinical trials...
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Abbott
NCT06474169 · Chronic Kidney Diseases
NCT07194590 · Chronic Kidney Disease (Stage 3-4), Vascular Function, and more
NCT07593352 · IBD and Renal Involement, Chronic Kidney Disease, and more
NCT07481526 · Chronic Kidney Disease
NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight
Gunma
Hokkaido
Ibaraki
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions